Background: Little is known about factors that influence hospice use for patients with blood cancers. We aimed to characterize hospice enrollment in a large population of patients with B-cell non-Hodgkin lymphoma (NHL) and assess the impact of disease characteristics such as aggressiveness and curability.
Approximately 79 000 cases of lymphoma are diagnosed each year in the United States, making it the most common hematologic malignancy (1) . Although lymphoma-related mortality has substantially improved in the past decade (2) (3) (4) , about 25% of patients still die of their disease each year, such that high-quality end-of-life (EOL) care is imperative. Hospice care is recognized as an essential component of such EOL care (5) . Several studies have demonstrated benefits of hospice enrollment including improved patient quality of life at the EOL and reduction in risk of psychiatric illness among bereaved caregivers (6) (7) (8) . A recent study also showed that patients with poor prognosis cancers receiving hospice care had lower rates of hospitalization, intensive care unit admissions, and lower total costs during the last year of life compared with those not enrolled in hospice (9) .
While specific data regarding hospice use for patients with lymphoma are sparse, the available literature indicates that patients with hematologic malignancies have lower rates of hospice utilization and shorter hospice stays compared with patients with solid malignancies (10) (11) (12) (13) (14) . Although these data raise concerns about the quality of EOL care for patients with hematologic cancers, little is known about hospice use among article patients with different types of lymphoma. Indeed, the heterogeneity of lymphoid cancers with respect to aggressiveness and curability offers an unparalleled opportunity to study the potential effect of both of these dimensions on hospice use for cancer patients.
We sought to characterize hospice utilization in a large population-based cohort of patients age 65 years or older who died with a B-cell non-Hodgkin lymphoma (NHL). We hypothesized that hospice use would be most prevalent in lymphoma disease states where disease aggressiveness and lack of curative options coincide. To test this, we assessed if patients with aggressive and incurable disease at baseline (mantle cell lymphoma [MCL] ) would be most likely to enroll. Additionally, we hypothesized that incurability would trump aggressiveness, such that patients with incurable and indolent lymphomas would be more likely to enroll in hospice compared to those with curable but aggressive disease.
Methods

Data Source
The primary source of data was the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) cancer registry linked to Medicare claims through December 31, 2010. SEER collects demographic, clinical, initial cancer-directed treatment, and survival data from 18 population-based cancer registries throughout the United States, covering approximately 28% of the population (15) . The sociodemographic characteristics of SEER patients are felt to be similar to those of the general population of the Unites States (16) . Ninety-seven percent of patients age 65 years and older are eligible for Medicare, with approximately 94% of those in the SEER registry matched to their Medicare enrollment and claims data (17) . The study was deemed exempt from review by the Dana-Farber/Harvard Cancer Center Institutional Review Board because we used publicly available de-identified data.
Cohort Assembly
The study cohort included all patients age 65 years and older who were diagnosed with any B-cell NHL as their only cancer diagnosis between January 1, 1999 and December 31, 2009 and who died between January 1, 1999 and December 31, 2009. We excluded patients who died within 30 days of their lymphoma diagnosis, as lack of hospice enrollment in such a short time frame after a cancer diagnosis may not be an accurate indicator of low-quality EOL care. We also required patients to be at least 66 years of age at death to determine comorbidity in the year prior to death. We divided the cohort into three groups: those with indolent NHLs that are largely incurable (chronic lymphocytic leukemia and follicular, marginal zone, and lymphoplasmacytic lymphoma), aggressive NHLs that are potentially curable (diffuse large B-cell, Burkitt, primary mediastinal B-cell, and primary effusion lymphoma), and MCL. MCL was considered a unique group because, while it is incurable like the indolent NHLs above, it usually has a more aggressive clinical course. To ascertain complete claims history for determining comorbidity status, patients had to have been continuously enrolled in both Medicare Parts A and B, with no health maintenance organization (HMO) enrollment during the 12 months prior to death. The cohort assembly strategy is detailed in Figure 1 .
Patients and Variables
Using the SEER-Medicare files, we determined each patient's sex, age, race, ethnicity, marital status, and year of death. We assessed comorbidity using the Deyo adaptation (18) of the Charlson Comorbidity Index (19) applied to both inpatient and outpatient claims for the 12 months prior to death. Median income quintiles were defined by census tract and ZIP code on the basis of available median household or per capita income. Education quintiles were determined based on the percentage of individuals age 25 years and older with some college education within a census tract. We also characterized each patient's geographic area of residence (urban, rural) and national region, and whether or not each patient had received chemotherapy within the last 30 days of life.
Outcomes
We first assessed hospice enrollment, defined as the presence of at least one hospice claim (outpatient or inpatient) in the Medicare Hospice file for a patient. For patients enrolled in hospice, we assessed the source of referral (outpatient vs inpatient) using a claims-based measure (20) . Inpatient referrals were defined as hospice enrollments that occurred within two days of hospital discharge, and other enrollments were defined as outpatient referrals. We next characterized length of stay, defined as the number of days between hospice admission and death, as well as the proportion of patients enrolled for three or more days and longer than a month, as per reported EOL care quality guidelines (21) . We also evaluated trends in overall hospice use, hospice enrollment three or more days, and hospice stay longer than one month over time. For the trend analysis, as with prior longitudinal studies of EOL care (22) , we restricted the cohort to patients who had a survival time of less than one year.
Statistical Analysis
We characterized hospice use in the overall cohort and in the three NHL groups as defined above and examined the characteristics of patients who enrolled versus those who did not. Univariate associations of patient characteristics and hospice enrollment were assessed using Chi-square tests for categorical variables and Wilcoxon tests for continuous variables. We then fit a multivariable logistic regression model to characterize factors associated with hospice use, including factors statistically significant in the univariate analyses. We conducted additional analyses to determine if differences in hospice use by lymphoma type existed when stratifying patients by receipt of chemotherapy within 30 days of death. Next, we performed sensitivity analyses restricting the cohort to those patients with cause of death listed as cancer to determine if differences in hospice use by lymphoma type were present among those most likely to have died of lymphoma. Trends in hospice use and length of stay over time were plotted using locally weighted scatterplot smoothing. We assessed significant trends over time using the Cochran-Armitage test. All P values presented are two-sided, and P values of less than .05 are considered statistically significant. All analyses were performed using SAS (version 9.4, Cary, NC).
Results
A total of 18 777 patients age 65 years and older were diagnosed with an indolent NHL, aggressive NHL, or MCL and died article between January 1, 1999 and December 31, 2009. Of the total cohort, 9645 (51.4%) had indolent NHL, 8226 (43.8%) had aggressive NHL, and 906 (4.8%) had MCL. The median diagnostic age of the total cohort was 79 years (80 years for indolent NHL, 79 years for aggressive NHL, and 77 years for MCL). Among the overall study cohort, 41.6% enrolled in hospice, 34.3% enrolled three or more days, and 12.7% enrolled longer than one month before death. 45.9% of hospice enrollments were within two days of hospital discharge. Among those enrolled in hospice, 78.1% utilized outpatient hospice services, 21.3% were admitted to inpatient hospice, and 0.6% used both. The median length of stay in hospice was 12 days. There were statistically significant differences in hospice use by lymphoma type, with 38.7% of indolent NHL patients, 44.3% of aggressive NHL patients, and 47.7% of MCL patients enrolling in hospice (P < .001). Additionally, 31.5% of indolent NHL patients, 37.2% of aggressive NHL patients, and 38.3% of MCL patients enrolled in hospice three or more days before death (P < .001). Median length of stay in hospice did not statistically differ among the three groups (12 days for both indolent and aggressive NHL, and 13 days for MCL, P = .16).
Patient sociodemographic and clinical characteristics are provided in Table 1 . In multivariable analysis (Table 2) The relationship between lymphoma type and hospice use remained when stratifying the cohort by receipt of chemotherapy within 30 days of death (Tables 3 and 4 ). For patients who received chemotherapy within 30 days of death (n = 3804), 27.1% enrolled in hospice, with 17.8% of this entire group enrolled three or more days before death. In this group, statistically significant differences persisted in hospice enrollment by type of NHL, with MCL patients having the highest odds of hospice use compared with patients with indolent NHL (OR = 1.87, 95% CI = 1.41 to 2.48), followed by patients with aggressive NHL (OR = 1.42, 95% CI = 1.20 to 1.68). Statistically significant differences in hospice use by NHL type persisted in sensitivity analyses restricting the overall cohort to patients whose cause of death was listed as cancer (n = 11 277; data not shown). Finally, Figures 2 and 3 show trends in hospice use, Among patients enrolled in hospice, the proportion with length of stay greater than a month was relatively constant (~25.0%) across all years, with no statistically significant trend upwards or downwards.
Discussion
In this large cohort of patients with lymphoma, we found the prevalence of hospice enrollment to be 41.6%, with only 34.3% enrolled at least three days before death. We also found that rates of hospice use varied in different types of NHL. While we confirmed our hypothesis that the aggressive and incurable MCL had the highest rate of use (47.7%), we were surprised to see that the potentially curable but aggressive lymphomas had higher rates of enrollment (44.3%) than those that were incurable and indolent (38.7%) at baseline. This finding suggests that disease aggressiveness at the EOL may be a more important driver of hospice use than having had an incurable disease all along. Although the overall rates of hospice use for the NHL patients we studied were higher than those previously reported for patients with hematologic cancers (11, 14, (23) (24) (25) , they were still substantially lower than the national averages reported for all Medicare patients with advanced cancer over a similar time period (53.8% for hospice enrollment; 43.3% enrolled ≥ 3 days) (26, 27) . Our data suggest substantial underuse of this vital EOL resource among lymphoma patients. Moreover, rates of timely hospice enrollment remained low even among those patients in our cohort who were not receiving aggressive care at the EOL (lack of chemotherapy close to death).
Underuse of hospice by lymphoma patients is likely partially because of oncologists' attitudes and patient preferences, but may also be an indication that the current hospice model is not meeting their specific EOL needs. Patients with lymphoma are less likely to be affected by chronic pain than those with other cancers. Indeed, pain control is a focus of our national hospice model, and as such, may be seen as less necessary for NHL patients at the EOL. Moreover, some lymphoma patients who might otherwise benefit may be reluctant to enroll because of the requirement to give up disease-directed therapy (28, 29) . The recent Medicare Care Choices Model project (30) , which aims to evaluate concurrent disease-directed care in a select group of hospice organizations, may help to address this issue.
MCL has the negative attributes of both aggressive and indolent NHL: Its disease course is often aggressive with most patients being symptomatic, and it is almost always incurable (31) . The combination of these factors (aggressive and incurable) may be clearer indicators of the EOL phase, when it occurs, for both lymphoma physicians and patients, leading to more timely discussions regarding hospice care. Moreover, prior research has shown that hematologic oncologists can have difficulty identifying the EOL phase, and aggressiveness may synergize with incurability to make this more readily evident (32) .
Our finding that a substantial proportion of transitions to hospice for lymphoma were likely made from the inpatient setting suggests that EOL conversations are occurring late and in the acute setting. Given prior literature demonstrating the association between EOL discussions and higher rates of timely hospice use (33, 34) , physician-targeted interventions to improve these discussions (35) using relevant clinical triggers have the potential to improve hospice use in this population. Additionally, system-level interventions to tailor hospice to the needs of lymphoma patients (eg, making transfusions feasible) may also improve enrollment.
Further study of the relationship between aggressiveness of disease and hospice use is warranted, as it may have important implications for EOL care for all patients with cancer. Although most advanced solid cancers are incurable, in certain disease types (eg, breast and ovarian cancer), a substantial number of patients have a prolonged and less-aggressive course (akin to indolent lymphoma), while others have a more rapid decline (similar to aggressive lymphoma). Indeed, a recent study of patients with metastatic breast cancer demonstrated that patients with an aggressive disease course had higher odds of We found disparities in hospice use similar to those previously observed in solid malignancies, with nonwhite patients and those of lower socioeconomic status (income and education) less likely to enroll (10, 12, 37, 38) . Men were also less likely to enroll. As with other cancers, such sex, race-ethnic, and socioeconomic disparities in EOL care for lymphoma patients may be addressable through physician and patient education regarding those most at risk and by improving the provision of culturally sensitive EOL care (41, 42) .
Although we found a statistically significant trend of increasing hospice use between 2000 and 2008, there was a concomitant decrease in the proportion of patients enrolled three or more days before death, a double trend that has also been demonstrated in solid malignancies (10, 20) . These findings suggest that gains in hospice were mostly for short-term enrollment and that patients may thus not be obtaining the full benefits that hospice can provide. On the other hand, for some patients with lymphoma who often still have a technically curable diagnosis near death, even short-term hospice may prevent further aggressive treatments that would have limited utility. As such, while interventions to improve timely use are needed for this population, more data are also needed as to the potential benefits of short-term enrollment.
We recognize limitations to our study. First, the fact that our cohort was restricted to patients age 65 years and older may * All percentages are row percentages. AOR = adjusted odds ratio; CI = confidence interval; MCL = mantle cell lymphoma; NHL = non-Hodgkin lymphoma. † Adjusted for sex, age, race, urban residency, college education quintile, median income quintile, geographic region, year of death, and time from diagnosis to death. ‡ Adjusted odds ratios greater than 1 indicate higher odds of enrolling in hospice. article limit the generalizability of our findings to younger populations. However, the median diagnostic age of most NHL is over 60 years so we are reassured of capturing a large portion of patients affected by lymphoma. Second, it is unclear whether the cause of death reported in SEER is the underlying or immediate cause of death. Thus, we cannot exclude the possibility that some patients died with lymphoma, and not necessarily from lymphoma. This limitation might be most problematic for patients with indolent NHL who did not need treatment at the EOL; however, it is notable that even when we restricted our cohort to patients who received chemotherapy close to death and ostensibly died of their lymphoma, the differences in hospice use by the three types of NHL persisted. Next, because SEER-Medicare data lag several years behind contemporaneous claims, we were unable to examine hospice use in the years beyond 2009. Finally, as SEER-Medicare data are observational and rely on claims, we could not ascertain the role of patient preferences or physician recommendations on the rates of hospice utilization; this is clearly an area that warrants further study. In summary, we found substantial underuse of hospice for patients with NHL and statistically significant differences by the aggressiveness and curability of the underlying subtype. In almost twenty years since the Institute of Medicine's landmark report "Approaching Death: Improving Care at the End of Life" (43) , great strides have been made to improve this phase of life for patients with advanced malignancies (44) (45) (46) . The hematologic cancers such as NHL have perhaps lagged behind because of their potential for late curability and lack of disease-specific data. Our analysis demonstrates that not only is there underuse of hospice among lymphoma patients but also that sociodemographic disparities exist. In addition, while enrollment was low overall, the rate for patients with MCL (47.7%) was closest to national rates for all cancers (53.8%), suggesting that the aggressiveness and incurability characteristic of MCL may help clarify when the EOL phase of disease is near.
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